SCHEMBL6893425

SCHEMBL6893425

CC(C)(O)C1CCN(c2nc3c(-c4cnc5ccccc5c4)cnn3c(N)c2Br)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.38
PDE10A Q9Y233 5/20 0.38
PIK3CA P42336 2/20 0.38
HPGDS O60760 1/20 0.38
EGFR P00533 3/20 0.37
FGFR2 P21802 3/20 0.37
PIK3CD O00329 1/20 0.36
CHEK1 O14757 4/20 0.36
CCNA2 P20248 4/20 0.36
CDK2 P24941 4/20 0.36
CCNA1 P78396 4/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893422 0.87 FGFR2 (0.40) PDE10APIK3CAEGFRFGFR2CHEK1
SCHEMBL6894496 0.85 NEK2 (0.41) PIK3CAEGFRFGFR2KDM4EALDH1A1
SCHEMBL6893442 0.84 PIK3CA (0.41) PIK3CAEGFRFGFR2PIK3CDCHEK1
SCHEMBL10234073 0.84 FGFR2 (0.41) PIK3CAEGFRFGFR2CHEK1CCNA2
SCHEMBL6893193 0.84 PDE4B (0.40) PDE10APIK3CAEGFRFGFR2CHEK1
SCHEMBL6893430 0.83 NPC1 (0.44) PIK3CAPIK3CDKDM4ENPC1ALDH1A1
SCHEMBL6893394 0.83 CHEK1 (0.37) PIM1EGFRFGFR2CHEK1CCNA2
SCHEMBL594559 0.83 PIK3CA (0.44) PDE10APIK3CA
SCHEMBL2680298 0.83 EGFR (0.40) PIK3CAEGFRFGFR2KDM4ENPC1
SCHEMBL10234123 0.83 CHEK1 (0.37) EGFRFGFR2CHEK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 PIM1 3818/4885PDE10A 3455/4885PIK3CA 2681/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR PIM1 255/4885PDE10A 3001/4885PIK3CA 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.